MCL1 and cancer: When we applied it to BCP-ALL, we found that trametinib as single agent only produced a modest cytotoxic effect on NALM-6 cells, but when sequentially combined with the MCL-1 inhibitor S63845, it reached an almost complete elimination of these cancer cells.